Format

Send to:

Choose Destination
See comment in PubMed Commons below
Target Oncol. 2010 Jun;5(2):119-29. doi: 10.1007/s11523-010-0148-3. Epub 2010 Aug 3.

Targeted therapies for non-clear renal cell carcinoma.

Author information

  • 1Department of Health and Human Services, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive Bldg 10 Rm 1-5940, Bethesda, MD 20892, USA. singerea@mail.nih.gov

Abstract

The treatment of advanced and metastatic kidney cancer has been revolutionized by the development of targeted systemic therapies. Despite the growing number of available agents approved for use against clear cell renal cell carcinoma, patients with non-clear histologies, constituting approximately 1 in 4 cases of kidney cancer, have not received the same attention. The majority of clinical trials testing novel targeted therapies have excluded non-clear subtypes, providing limited therapeutic options for patients with these diagnoses and their oncologists. This review will focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma: papillary I and II, chromophobe, and collecting duct. The unique genetic and molecular profiles of each distinct non-clear kidney cancer subtype will be described, as these differences are integral to the development and effectiveness of the novel agents used to treat them. Trials focusing on non-clear kidney cancer, or those that treated clear cell tumors along with significant numbers of non-clear subtypes, will be discussed. The role of cytoreductive nephrectomy and the use of neoadjuvant and adjuvant targeted therapy will be reviewed. Lastly, areas of future research will be highlighted.

PMID:
20680492
[PubMed - indexed for MEDLINE]
PMCID:
PMC3003336
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk